Cargando…

Potential of uPAR, αvβ6 Integrin, and Tissue Factor as Targets for Molecular Imaging of Oral Squamous Cell Carcinoma: Evaluation of Nine Targets in Primary Tumors and Metastases by Immunohistochemistry

No clinically approved tumor-specific imaging agents for head and neck cancer are currently available. The identification of biomarkers with a high and homogenous expression in tumor tissue and minimal expression in normal tissue is essential for the development of new molecular imaging targets in h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lawaetz, Mads, Christensen, Anders, Juhl, Karina, Karnov, Kirstine, Lelkaitis, Giedrius, Kanstrup Fiehn, Anne-Marie, Kjaer, Andreas, von Buchwald, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962929/ https://www.ncbi.nlm.nih.gov/pubmed/36835265 http://dx.doi.org/10.3390/ijms24043853

Ejemplares similares

Diagnostic Value of Preoperative uPAR-PET/CT in Regional Lymph Node Staging of Oral and Oropharyngeal Squamous Cell Carcinoma: A Prospective Phase II Trial
por: Lawaetz, Mads, et al.
Publicado: (2023)

Improved surgical resection of metastatic pancreatic cancer using uPAR targeted in vivo fluorescent guidance: comparison with traditional white light surgery
por: Juhl, Karina, et al.
Publicado: (2019)

Expression patterns of uPAR, TF and EGFR and their potential as targets for molecular imaging in oropharyngeal squamous cell carcinoma
por: Christensen, Anders, et al.
Publicado: (2022)

uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: proof-of-concept in orthotopic xenograft model
por: Christensen, Anders, et al.
Publicado: (2016)

Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer
por: Christensen, Anders, et al.
Publicado: (2017)

Integrin is on uPAR to unleash cells
por: LeBrasseur, Nicole
Publicado: (2003)

IRDye800CW labeled uPAR-targeting peptide for fluorescence-guided glioblastoma surgery: Preclinical studies in orthotopic xenografts
por: Kurbegovic, Sorel, et al.
Publicado: (2021)

The use of a uPAR-targeted probe for photothermal cancer therapy prolongs survival in a xenograft mouse model of glioblastoma
por: Simón, Marina, et al.
Publicado: (2021)

Peptide-Based Optical uPAR Imaging for Surgery: In Vivo Testing of ICG-Glu-Glu-AE105
por: Juhl, Karina, et al.
Publicado: (2016)

Data on the regulation of moesin and merlin by the urokinase receptor (uPAR): Model explaining distal activation of integrins by uPAR
por: Degryse, Bernard, et al.
Publicado: (2017)

Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221
por: Falkenberg, Natalie, et al.
Publicado: (2015)

Targeted imaging of uPAR expression in vivo with cyclic AE105 variants
por: Leth, Julie Maja, et al.
Publicado: (2023)

Diagnostic accuracy of combined optical- and radio-guided SNB for neck staging of oral squamous cell carcinoma lesions in the anterior oral cavity
por: Christensen, Anders, et al.
Publicado: (2023)

Identification of a New Epitope in uPAR as a Target for the Cancer Therapeutic Monoclonal Antibody ATN-658, a Structural Homolog of the uPAR Binding Integrin CD11b (αM)
por: Xu, Xiang, et al.
Publicado: (2014)

Correction: Identification of a New Epitope in uPAR as a Target for the Cancer Therapeutic Monoclonal Antibody ATN-658, a Structural Homolog of the uPAR Binding Integrin CD11b (αM)
Publicado: (2014)

Correction: Identification of a New Epitope in uPAR as a Target for the Cancer Therapeutic Monoclonal Antibody ATN-658, a Structural Homolog of the uPAR Binding Integrin CD11b (αM)
Publicado: (2014)

Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications
por: Persson, Morten, et al.
Publicado: (2013)

The uPAR System as a Potential Therapeutic Target in the Diseased Eye
por: Cammalleri, Maurizio, et al.
Publicado: (2019)

First-in-human uPAR PET: Imaging of Cancer Aggressiveness
por: Persson, Morten, et al.
Publicado: (2015)

uPAR-targeted multimodal tracer for pre- and intraoperative imaging in cancer surgery
por: Boonstra, Martin C., et al.
Publicado: (2015)

Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion
por: Annis, Matthew G., et al.
Publicado: (2018)

uPAR's signaling two step
por: Leslie, Mitch
Publicado: (2007)

Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors
por: Oh, Felix, et al.
Publicado: (2020)

uPAR-targeted Optical Imaging Contrasts as Theranostic Agents for Tumor Margin Detection
por: Yang, Lily, et al.
Publicado: (2013)

Urokinase Plasminogen Activator Receptor (uPAR) Targeted Nuclear Imaging and Radionuclide Therapy
por: Li, Dan, et al.
Publicado: (2013)

The anti-tumoral potential of the saporin-based uPAR-targeting chimera ATF-SAP
por: Zuppone, S., et al.
Publicado: (2020)

Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer
por: Zhai, Bing-Tao, et al.
Publicado: (2022)

Human antibody V(H) domains targeting uPAR as candidate therapeutics for cancers
por: Chu, Xiaojie, et al.
Publicado: (2023)

Effect of near infrared autofluorescence guided total thyroidectomy on postoperative hypoparathyroidism: a randomized clinical trial
por: Lykke, Eva, et al.
Publicado: (2023)

uPAR: An Essential Factor for Tumor Development
por: Lv, Tao, et al.
Publicado: (2021)

Urokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancer
por: Montuori, Nunzia, et al.
Publicado: (2016)

Targeting uPAR by CRISPR/Cas9 System Attenuates Cancer Malignancy and Multidrug Resistance
por: Wang, Kun, et al.
Publicado: (2019)

EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells
por: Laurenzana, Anna, et al.
Publicado: (2019)

The Urokinase Receptor (uPAR) as a “Trojan Horse” in Targeted Cancer Therapy: Challenges and Opportunities
por: Metrangolo, Virginia, et al.
Publicado: (2021)

Development of AE147 Peptide-Conjugated Nanocarriers for Targeting uPAR-Overexpressing Cancer Cells
por: Park, June Yong, et al.
Publicado: (2021)

uPAR directed-imaging of head-and-neck cancer
por: Baart,, Victor M., et al.
Publicado: (2017)

Crystal structure and cellular functions of uPAR dimer
por: Yu, Shujuan, et al.
Publicado: (2022)

Retraction: uPAR/Cathepsin B Overexpression Reverse Angiogenesis by Rescuing FAK Phosphorylation in uPAR/Cathepsin B Down Regulated Meningioma
Publicado: (2020)

Suppression of uPAR Retards Radiation-Induced Invasion and Migration Mediated by Integrin β1/FAK Signaling in Medulloblastoma
por: Nalla, Arun Kumar, et al.
Publicado: (2010)

A doxycycline-inducible urokinase receptor (uPAR) upregulates uPAR activities including resistance to anoikis in human prostate cancer cell lines
por: Hasanuzzaman, Mohammad, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_5lcer46hoainapreofm1upiqau